AstraZeneca PLC Total Voting Rights (9484J)
July 03 2017 - 10:00AM
UK Regulatory
TIDMAZN
RNS Number : 9484J
AstraZeneca PLC
03 July 2017
3 July 2017 15:00 BST
Transparency Directive
Voting Rights and Capital
The following notification is made in accordance with the UK
Financial Conduct Authority's Disclosure and Transparency Rule
5.6.1. As at 30 June 2017 the issued share capital of AstraZeneca
PLC with voting rights is 1,265,775,103 ordinary shares of US$0.25.
No shares are held in Treasury. Therefore, the total number of
voting rights in AstraZeneca PLC is 1,265,775,103.
The above figure for the total number of voting rights may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, AstraZeneca PLC
under the UK Financial Conduct Authority's Disclosure and
Transparency Rules.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and follow us on Twitter
@AstraZeneca.
Media Relations
Esra Erkal-Paler UK/Global +44 203 749 5638
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711
US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRLLFFFDRIVIID
(END) Dow Jones Newswires
July 03, 2017 10:00 ET (14:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
